- Home
- CNTX vs SLGL Comparison
CNTX vs SLGL Comparison
Compare CNTX & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTX | SLGL |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.7M | 117.8M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CNTX | SLGL |
|---|---|---|
| Price | $1.54 | $42.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $5.67 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 730.1K | 20.5K |
| Earning Date | 11-05-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $0.49 | $4.02 |
| 52 Week High | $1.55 | $52.26 |
Technical Indicators
Market Signals| Indicator | CNTX | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 72.39 | 52.80 |
| Support Level | $1.09 | $40.10 |
| Resistance Level | $1.34 | $44.99 |
| Average True Range (ATR) | 0.13 | 2.97 |
| MACD | 0.04 | -0.22 |
| Stochastic Oscillator | 88.14 | 55.31 |
Price Performance
Historical ComparisonAbout CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.